Clinical trial
Camrelizumab Plus Apatinib as Maintenance Treatment in Extensive-stage SCLC With a Response or Stable Disease After Standard Chemotherapy: A Single-arm, Prospective Clinical Trial
NCT04901754 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Camrelizumab Plus Apatinib as Maintenance Treatment in Extensive-stage SCLC With a Response or Stable Disease After Standard Chemotherapy: A Single-arm, Prospective Clinical Trial
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 14, 2021
- Completion date
- March 31, 2023
- Enrollment
- 38 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.